Search

everythinglearnresearchcommunity

for

Search:↓

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Intralesional triamcinolone acetonide can regrow hair in alopecia areata but often has temporary effects and side effects.

Alopecia Areata is an autoimmune disease affecting hair follicles, influenced by genetic and environmental factors, with rodent models being essential for research.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.

Non-immune factors play a significant role in alopecia areata.

Horizontal scalp biopsy sections are better for diagnosing alopecia areata, showing fewer hair follicles and more miniaturized hairs.

Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.

Nonsteroid treatments for alopecia areata show promise but need more high-quality research.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Less than a quarter of alopecia areata cases were unusual forms or had paradoxical regrowth.

People with alopecia areata have higher levels of RBP4 protein and antibodies against it.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Alopecia areata in US adolescents leads to significant healthcare costs and usage.

A severe medication reaction required long treatment and led to hair loss and thyroid issues.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Oral Apremilast effectively treats alopecia areata in most patients.

Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.

Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.

People with Alopecia Areata often have thyroid problems like Hashimoto thyroiditis and hypothyroidism.

Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.

The conclusion is that emotional support and a variety of treatments are important for alopecia areata, but more research is needed.

There's no link between low iron levels and the hair loss condition, alopecia areata.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.